NETHERLANDS – Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has sealed a US$586 million, three-target agreement with Macrogenics…
Read MoreSynaffix inks ADC tech deal with MacroGenics
